A leading solution in target deconvolution and receptor identification
Retrogenix provides the leading solution for receptor and membrane target deconvolution. We specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses.
Retrogenix identifies on behalf of its clients:
Target deconvolution is achieved by screening our clients’ molecules for interactions against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 3500 proteins, this represents the majority of known plasma membrane proteins.
Retrogenix has a rich client portfolio, including many global pharmaceutical / drug discovery companies and several notable academic institutions. We give our commercial clients a competitive advantage by identifying high quality, unexploited drug targets, and helping them to improve success rates at all stages of the drug research and development process.
29/07/2015 | Retrogenix co-founders meet HM the Queen at Buckingham Palace reception. We are delighted to report that staff at Retrogenix have this month received royal recognition for the development and commercialization of the company's proprietary human cell microarray technology. Retrogenix's... | Read More
Retrogenix will be attending the 21st Annual Biotechnology-Derived Therapeutics: Perspectives on Nonclinical Development Symposium on the 28th, 29th and 30th September in San Diego, USA | Find out more
“…"no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool” | Read more
Professor Thomas Lavstsen, University of Copenhagen